Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2020

View Archived Issues

IRDye800CW-nimotuzumab enters phase I/II study for image-guided lung cancer surgery

Q32 Bio begins phase I study with ADX-914 in healthy volunteers

Regeneron initiates phase I study of NPR1 agonist REGN-5381

Prion protein's positive point

"Fight or flight" nervous system helps fight tumors, too

Preliminary results support ongoing development of Biogen's BTK inhibitor

Dosing starts in phase I study of exoIL-12

EMA approves label update for HyQvia

Arbutus presents continued positive data from first-in-human study of AB-729

SAB-402, a novel potent dual EGFR/HER4 tyrosine kinase inhibitor with promising activity in vivo

Specific PAC1 receptor antibody as potential new treatment of primary headaches

RNA-targeted CRISPR reverses myotonic dystrophy symptoms

Bioardis divulges new FGFR4 inhibitors

C4 Therapeutics patents new CRBN-targeting compounds

Bristol-Myers Squibb identifies TYK2 inhibitors

FDA clears IND for bispecific antibody EMB-02 for solid tumors

AC Immune identifies new MAPT aggregation inhibitors

Sec61 protein secretion-interfering compounds presented by Kezar Life Sciences

New animal model created to study cerebellar dysfunction in multiple sclerosis

Phase III trial of ganaxolone in CDKL5 deficiency disorder meets primary endpoint

AQP4 and Cx43 expression alteration leads to neuromyelitis optica

Escient initiates phase I/Ib study of EP-547 to treat cholestatic and uremic pruritus

New preclinical data reported on ICON-2 for solid tumors

Grant supports Melior's evaluation of tolimidone for COVID-19

Innovation Pharmaceuticals reports new in vitro data on use of brilacidin for COVID-19

Lilly reports interim phase II data on SARS-CoV-2 neutralizing antibody LY-CoV555

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...